Last reviewed · How we verify
Octohydroaminoacridine Succinate Tablets
At a glance
| Generic name | Octohydroaminoacridine Succinate Tablets |
|---|---|
| Sponsor | Changchun Huayang High-tech Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease (PHASE3)
- Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: